Psychedelic Research and Access in
Kenya
Kenya has a small, lightly mapped psychedelic ecosystem in Blossom. The page currently links to one stakeholder and does not link to a country-specific psychedelic clinical trial, so the profile should be read as a cautious access and ecosystem note rather than a mature research-country page.
Data updated
Key Insights
A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inKenya.
- 1
Blossom currently links Kenya to one psychedelic stakeholder and no country-linked psychedelic clinical trials.
- 2
The strongest public evidence is regulatory rather than clinical: Kenyan law and pharmacy rules point to controlled access, not open therapeutic availability.
- 3
Ketamine should be distinguished from classic psychedelics because it has recognised medical roles but does not imply psychedelic-assisted therapy access.
- 4
Future updates should prioritise verified Kenyan regulator, ethics-board, university, or hospital sources before adding stronger research claims.
- 5
The country access guide currently classifies access as "Medical Only (Private)"; details should be checked compound by compound.
Research and Access Snapshot
Blossom currently tracks no country-linked psychedelic clinical trials for Kenya, but the page does include 1 stakeholder.
Blossom has not linked country-level trial records yet. Treat this as a coverage gap, not proof that no local policy discussion, care, or informal activity exists.
- Active trials
- 0
- Total trials
- 0
- Stakeholders
- 1
- Events
- 0
None marked active
No linked trials
Linked organisations
No linked events
Top Compounds
Linked country trials do not show a leading compound yet.
Top Study Topics
Linked country trials do not show a leading study topic yet.
Medical Access
Kenya maintains a restrictive national control regime for narcotics and psychotropic substances under the Narcotic Drugs and Psychotropic Substances (Control) Act (Cap. 245), which broadly prohibits unauthorized possession, manufacture, trafficking and use of many classic psychedelics while preserving medical/regulated channels for legitimately recognized medicines. In practice, conventional psychedelics (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca, mescaline, 2C-X) are classified under the general narcotics/psychotropic controls and have no...
Regulatory Status
Kenya appears to maintain a restrictive controlled-substances framework for classic psychedelics. The Narcotic Drugs and Psychotropic Substances (Control) Act and Pharmacy and Poisons rules provide the relevant legal context, including controls on named psychotropic substances and approvals for import or manufacture. On the evidence reviewed, classic psychedelics should not be described as routinely medically available; any research or medical use would likely require case-by-case regulatory and institutional approval.
Country Details
- Region
- Africa
- Last updated
- 4 May 2026
Country Report
Medical Only (Private)Medical Access
Kenya maintains a restrictive national control regime for narcotics and psychotropic substances under the Narcotic Drugs and Psychotropic Substances (Control) Act (Cap. 245), which broadly prohibits unauthorized possession, manufacture, trafficking and use of many classic psychedelics while...
Open access guide →Pro Scorecard
Country Scorecard
Compare evidence, access, payment, delivery, local ecosystem, and review confidence for Kenya.
Open scorecard →Psychedelic Stakeholders in Kenya
Organisations, sponsors, clinics, and research groups connected to psychedelic science in Kenya.